Testing immune-cell treatments for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests immune-based treatments (called PDO, PDO-TIL, and PDOTS) for people with liver cancer that has spread or can’t be removed by surgery. It aims to see how well these treatments work and how safely they can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have liver cancer (including liver cancer that has spread) and at least one measurable tumor spot
- You are fairly active (ECOG 0–1, meaning you can do most daily activities)
- Your key organs (like liver, kidneys, and blood counts) are working well enough for treatment
- If you can become pregnant or father a child, you must use approved birth control during the study and for 3 months after
- You must sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It is for people whose cancer has progressed after at least two standard treatments and who have tumors that can be biopsied to grow these cells.
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
This study is for people with advanced liver cancer who are starting a new type of treatment that combines targeted therapy to block blood vessel growth and immune therapy to help your body fight the cancer. It looks at how gut bacteria might affect treatment response.
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.